Related Experiment Video
Updated: Sep 14, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)
Amanda Herrmann1, Tali Azenkot1, Van Hilburn2
1Division of Hematology-Oncology, University of California San Diego Moores Cancer Center, San Diego, CA, USA.
Introduction:
Oncogenic activation of KRAS is a common driver of solid tumor malignancies and has been considered 'undruggable' for several decades. Oral small molecule inhibitors, including sotorasib and adagrasib, have demonstrated moderate efficacy in targeting KRAS G12C in NSCLC. More potent inhibitors are needed, and the landscape is rapidly evolving.
Areas Covered:
Opnurasib (JDQ-443) is an irreversible covalent inhibitor of GDP-bound KRAS G12C that has been under investigation in patients with KRAS G12C-mutated solid tumors, including NSCLC. Here, we review its mechanism of action, pharmacologic properties, clinical efficacy, role within the NSCLC landscape prior to its withdrawal from the market, as well as the regulatory and market-driven dynamics that may result in the abandonment of aspiring drugs.
Expert Opinion:
JDQ-443's unique binding within the Switch II pocket of KRAS G12C allows for novel interactions and helps define its characteristic profile of anti-tumor activity, tolerability, and resistance. JDQ-443 has demonstrated promising early clinical activity in KRAS G12C-mutated NSCLC. More data is necessary to allow comparison of available agents and combination strategies. In the face of an expanding market, development of JDQ-443 has been halted despite promising safety and efficacy outcomes and ongoing innovative trials, highlighting critical challenges in the drug development process. The existing body of work characterizing JDQ-443 remains extremely informative.
Insights
Opnurasib (JDQ-443) showed promise as a KRAS G12C inhibitor for NSCLC, but its development was halted. This highlights challenges in drug development despite positive early clinical activity and safety outcomes.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- KRAS mutations drive many solid tumors and have historically been difficult to target.
- Existing KRAS G12C inhibitors like sotorasib and adagrasib show moderate efficacy in NSCLC.
- There is a need for more potent KRAS inhibitors to improve patient outcomes.
Purpose of the Study:
- To review the mechanism of action, pharmacologic properties, and clinical efficacy of Opnurasib (JDQ-443).
- To discuss the role of JDQ-443 in the NSCLC treatment landscape.
- To examine the regulatory and market dynamics leading to the discontinuation of JDQ-443 development.
Main Methods:
- Review of preclinical and clinical data for JDQ-443.
- Analysis of KRAS G12C inhibitor landscape in NSCLC.
- Examination of drug development challenges and market factors.
Main Results:
- JDQ-443 demonstrated a unique binding profile and promising early clinical activity in KRAS G12C-mutated NSCLC.
- The drug exhibited a characteristic profile of anti-tumor activity, tolerability, and resistance.
- Despite positive safety and efficacy signals, JDQ-443 development was halted.
Conclusions:
- JDQ-443 presented a novel approach to targeting KRAS G12C with promising early results.
- The discontinuation of JDQ-443 underscores the complexities and challenges in pharmaceutical development.
- Further research and data are needed to compare JDQ-443 with other agents and combination strategies.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:11Clinical Trials: Overview
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...